These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 4461148)

  • 1. Letter: Abrupt withdrawal of antiparkinsonian drugs in chronic schizophrenic patients.
    McLelland HA; Blessed G; Bhate S
    Br J Psychiatry; 1974 Nov; 125():514-5. PubMed ID: 4461148
    [No Abstract]   [Full Text] [Related]  

  • 2. The abrupt withdrawal of antiparkinsonian drugs in schizophrenic patients.
    McClelland HA; Blessed G; Bhate S; Ali N; Clarke PA
    Br J Psychiatry; 1974 Feb; 124(579):151-9. PubMed ID: 4596671
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluating the long-term need for antiparkinson drugs by chronic schizophrenics.
    Klett CJ; Caffey E
    Arch Gen Psychiatry; 1972 Apr; 26(4):374-9. PubMed ID: 4552131
    [No Abstract]   [Full Text] [Related]  

  • 4. [Antagonism between anti-Parkinson drugs and neuroleptics. Apropos of various withdrawal experiences, a personal one among them (2nd part)].
    Bourgeois M; Bouey P
    Ann Med Psychol (Paris); 1976 Nov; 2(4):669-708. PubMed ID: 1020864
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effects of neuroleptic withdrawal on the drug-induced extrapyramidal syndrome of chronic schizophrenia].
    Elie R; Gagnon MA; Gauthier R; Jéquier JC
    Union Med Can; 1975 Jun; 104(6):909-14. PubMed ID: 772906
    [No Abstract]   [Full Text] [Related]  

  • 6. Assessment of drugs in schizophrenia. Discussion on assessment of drug-induced extrapyramidal reactions.
    McClelland HA
    Br J Clin Pharmacol; 1976 Jun; 3(3 Suppl 2):401-3. PubMed ID: 9966
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevention and management of tardive dyskinesia.
    Crane GE
    Am J Psychiatry; 1972 Oct; 129(4):466-7. PubMed ID: 5071149
    [No Abstract]   [Full Text] [Related]  

  • 8. Prophylactic antiparkinson drug use: II. Withdrawal after long-term maintenance therapy.
    Lavin MR; Rifkin A
    J Clin Pharmacol; 1991 Aug; 31(8):769-77. PubMed ID: 1679063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use in psychiatry of antiparkinson drugs].
    Bourgeois M; Mazaux JM; Imbert D; Daubech MJ; Daulouède JP; Tignol J
    Ann Med Psychol (Paris); 1976 Oct; 2(3):499-510. PubMed ID: 1020859
    [No Abstract]   [Full Text] [Related]  

  • 10. Neuroleptic induced extrapyramidal symptoms.
    Donlon PT; Stenson RL
    Dis Nerv Syst; 1976 Nov; 37(11):629-35. PubMed ID: 136337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of extrapyramidal adverse effects in neuroleptic therapy].
    Malm U
    Nord Psykiatr Tidsskr; 1972; 26(6):348-50. PubMed ID: 4634569
    [No Abstract]   [Full Text] [Related]  

  • 12. Gradual withdrawal of antiparkinson medication in chronic schizophrenics: any better than the abrupt?
    Manos N; Gkiouzepas J; Tzotzoras T; Tzanetoglou A
    J Nerv Ment Dis; 1981 Oct; 169(10):659-61. PubMed ID: 6116743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Some methodological considerations in the evaluation of drug-induced extrapyramidal disorders: a study of Ex10-029, a new morphanthridine derivative.
    Simpson GM; Beckles D; Isalski Z; Lee JH
    J Clin Pharmacol New Drugs; 1972 Apr; 12(4):142-52. PubMed ID: 4553448
    [No Abstract]   [Full Text] [Related]  

  • 14. Antiparkinsonian agents and fluphenazine decanoate.
    Idzorek S
    Am J Psychiatry; 1976 Jan; 133(1):80-2. PubMed ID: 1247126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of antiparkinsonian drugs during neuroleptic treatment and the effect of clonazepam on akathisia and parkinsonism occurred after antiparkinsonian drug withdrawal: a double-blind study.
    Horiguchi J; Nishimatsu O
    Jpn J Psychiatry Neurol; 1992 Sep; 46(3):733-9. PubMed ID: 1362592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study of the delayed-action form of a synthetic antiparkinsonian drug: Akineton].
    Kammerer T; Schweitzer-Bucher E; Jamet P; Royer M
    Ann Med Psychol (Paris); 1972 May; 1(5):688-96. PubMed ID: 5081112
    [No Abstract]   [Full Text] [Related]  

  • 17. [Withdrawal of antiparkinson drugs in long term neuroleptic treatment].
    Lerner J; Blum E; Fuchs I; Grinberg M
    Harefuah; 1978 Oct; 95(8):239-41. PubMed ID: 33879
    [No Abstract]   [Full Text] [Related]  

  • 18. The rabbit syndrome and antiparkinsonian medication in schizophrenic patients.
    Wada Y; Yamaguchi N
    Neuropsychobiology; 1992; 25(3):149-52. PubMed ID: 1357583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Trial of interruption of antiparkinson drugs in long term treatments with neuroleptics].
    Caroli F; Littre-Poirier MF; Ginestet D; Deniker P
    Encephale; 1975; 1(1):69-74. PubMed ID: 805695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-induced extrapyramidal side-effects in Egyptian schizophrenic patients.
    Okasha A; El Okbi H; Sadek A; Lotiaf F; Ashour AM
    Egypt J Psychiatry; 1979 Oct; 2(2):191-7. PubMed ID: 45368
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.